Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 146 Carcinoma, Non-Small-Cell Lung 112 Carcinoma, Renal Cell 74 Neoplasm Metastasis 53 Carcinoma, Hepatocellular 51 Squamous Cell Carcinoma of Head and Neck 50 Lung Neoplasms 48 Colorectal Neoplasms 34 Pancreatic Neoplasms 30 Neoplasms 30 Hodgkin Disease 30 Urinary Bladder Neoplasms 24 Sarcoma 23 Brain Neoplasms 23 Stomach Neoplasms 22 Head and Neck Neoplasms 21 Breast Neoplasms 21 Prostatic Neoplasms 20 Carcinoma, Transitional Cell 20 Glioblastoma 19 Recurrence 17 Colonic Neoplasms 17 Kidney Neoplasms 16 Uveal Melanoma 15 Small Cell Lung Carcinoma 15 Multiple Myeloma 15 Esophageal Neoplasms 15 Carcinoma, Squamous Cell 14 Skin Neoplasms 13 Leukemia, Myeloid, Acute 13

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Nivolumab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡